Last reviewed · How we verify
Rina-S
Rina-S is a bispecific antibody that simultaneously engages two immune checkpoints to enhance T-cell activation and anti-tumor immunity.
Rina-S is a bispecific antibody that simultaneously engages two immune checkpoints to enhance T-cell activation and anti-tumor immunity. Used for Advanced or metastatic solid tumors (Phase 3 development).
At a glance
| Generic name | Rina-S |
|---|---|
| Also known as | PRO1184, Rinatabart sesutecan, GEN1184, Rinatabart Sesutecan |
| Sponsor | Genmab |
| Drug class | Bispecific antibody |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Rina-S is designed to bind and modulate multiple immune pathways to overcome tumor immune evasion. By targeting dual checkpoints, the drug aims to provide a more potent immune activation than single-checkpoint inhibitors, potentially improving efficacy in difficult-to-treat cancers.
Approved indications
- Advanced or metastatic solid tumors (Phase 3 development)
Common side effects
- Immune-related adverse events
- Infusion reactions
Key clinical trials
- Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer (PHASE2)
- Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy (PHASE3)
- Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) (PHASE1, PHASE2)
- Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer (PHASE3)
- Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rina-S CI brief — competitive landscape report
- Rina-S updates RSS · CI watch RSS
- Genmab portfolio CI